CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 168 filers reported holding CLOVIS ONCOLOGY INC in Q1 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,184,000 | +46.2% | 168,700 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $810,000 | -26.0% | 168,700 | -10.1% | 0.00% | 0.0% |
Q3 2020 | $1,094,000 | +10.7% | 187,683 | +28.3% | 0.00% | 0.0% |
Q2 2020 | $988,000 | +51.3% | 146,300 | +42.6% | 0.00% | 0.0% |
Q1 2020 | $653,000 | -73.8% | 102,600 | -57.1% | 0.00% | -50.0% |
Q4 2019 | $2,493,000 | +855.2% | 239,116 | +260.7% | 0.00% | – |
Q3 2019 | $261,000 | -69.2% | 66,300 | +16.3% | 0.00% | -100.0% |
Q2 2019 | $848,000 | -41.0% | 57,000 | -1.6% | 0.00% | -50.0% |
Q1 2019 | $1,437,000 | +34.4% | 57,900 | -2.7% | 0.00% | +100.0% |
Q4 2018 | $1,069,000 | -44.4% | 59,500 | -9.0% | 0.00% | -50.0% |
Q3 2018 | $1,921,000 | -40.3% | 65,400 | -7.6% | 0.00% | -50.0% |
Q2 2018 | $3,219,000 | -28.2% | 70,800 | -16.6% | 0.00% | -33.3% |
Q1 2018 | $4,483,000 | -32.2% | 84,900 | -12.6% | 0.01% | -33.3% |
Q4 2017 | $6,609,000 | +140.2% | 97,184 | +191.1% | 0.01% | +125.0% |
Q3 2017 | $2,751,000 | -1.8% | 33,384 | +11.7% | 0.00% | 0.0% |
Q2 2017 | $2,800,000 | +59.4% | 29,900 | +8.3% | 0.00% | +33.3% |
Q1 2017 | $1,757,000 | +58.9% | 27,600 | +10.8% | 0.00% | +50.0% |
Q4 2016 | $1,106,000 | +23.2% | 24,900 | 0.0% | 0.00% | +100.0% |
Q3 2016 | $898,000 | +145.4% | 24,900 | -6.7% | 0.00% | 0.0% |
Q2 2016 | $366,000 | -30.9% | 26,700 | -3.3% | 0.00% | 0.0% |
Q1 2016 | $530,000 | -48.5% | 27,600 | -6.1% | 0.00% | -50.0% |
Q4 2015 | $1,029,000 | -68.8% | 29,400 | -18.1% | 0.00% | -66.7% |
Q3 2015 | $3,301,000 | +11.1% | 35,900 | +6.2% | 0.01% | +50.0% |
Q2 2015 | $2,970,000 | +14.2% | 33,800 | -11.1% | 0.00% | 0.0% |
Q1 2015 | $2,601,000 | 0.0% | 38,002 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $2,601,000 | +411.0% | 38,002 | +238.8% | 0.00% | +300.0% |
Q3 2014 | $509,000 | +45.8% | 11,216 | +33.1% | 0.00% | – |
Q2 2014 | $349,000 | -33.9% | 8,427 | +4.4% | 0.00% | -100.0% |
Q1 2014 | $528,000 | +1127.9% | 8,071 | +1053.0% | 0.00% | – |
Q3 2013 | $43,000 | -99.7% | 700 | -99.7% | 0.00% | -100.0% |
Q2 2013 | $15,670,000 | – | 233,943 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |